<DOC>
	<DOC>NCT02683226</DOC>
	<brief_summary>The purpose of this study was to determine whether dual treatment with metformin and alogliptin is more effective than treatment with metformin, alogliptin and pioglitazone in the treatment of obese women with polycystic ovary syndrome (PCOS) regarding insulin resistance and beta cell function.</brief_summary>
	<brief_title>Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>18 years old to menopause polycystic ovary syndrome (NICHD criteria) BMI of 30 kg/mÂ² or higher type 1 or type 2 diabetes mellitus history of carcinoma Cushing's syndrome or congenital (nonclassic) adrenal hyperplasia personal or family history of MEN 2 significant cardiovascular, kidney or hepatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>